X4 Pharmaceuticals Q3 EPS $(0.01) Beats $(0.15) Estimate. Cash and Equivalents $142.7M
Portfolio Pulse from Benzinga Newsdesk
X4 Pharmaceuticals reported Q3 losses of $(0.01) per share, beating the analyst consensus estimate of $(0.15) by 93.33%. This is a 96.15% increase over losses of $(0.26) per share from the same period last year. The company's cash and equivalents stand at $142.7M.
November 09, 2023 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
X4 Pharmaceuticals reported better than expected Q3 losses, which could positively impact the stock in the short term. The company's strong cash position also adds to its financial stability.
X4 Pharmaceuticals reported a smaller loss than expected, which is generally seen as a positive sign by investors. This could lead to increased investor confidence and a potential rise in the stock price. Additionally, the company's strong cash position indicates good financial health, which could further boost investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100